Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?
ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Senior Housing News2d
Trustwell Living Doubles Down on Data in Search of New Competitive Advantage
This article is part of your SHN+ subscription In 2025, the baby boomer generation is standing at the industry’s doorstep.
The Manila Times4d
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...
The Pharma Letter5d
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
Heron Therapeutics: Four Horse Race Of Approved Therapies
Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last Hold rating in November 2024.
Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought - Downgrade
Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The Furoscix 80 mg/10 ml subcutaneous injection is intended for oedema in adult CKD patients, including those with nephrotic ...
The American Journal of Managed Care7d
FDA Expands Furosemide Injection Label to Treat Edema in CKD
Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.
The Pharma Letter7d
FDA nod for scPharmaceuticals’ Furoscix sNDA
Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...
Medindia7d
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
(9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Based on the feedback from the FDA, the Company’s regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation. Axsome ...
Axsome Therapeutics expects to submit sNDA for AXS-05 in Q3
Axsome Therapeutics (AXSM) has received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting a ...